Difference between revisions of "Acute myeloid leukemia, IDH-mutated"
Jump to navigation
Jump to search
(page editor) |
m |
||
| Line 2: | Line 2: | ||
<!--Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].--> | <!--Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].--> | ||
| − | + | {| class="wikitable" style="text-align:center; width:50%;" | |
| − | |||
| − | {| class="wikitable" style="text-align:center; width: | ||
! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Page editor''' | ! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Page editor''' | ||
|- | |- | ||
| Line 11: | Line 9: | ||
|- | |- | ||
|} | |} | ||
| + | <big>'''Note: these are biomarker-specific regimens for patients with IDH1 or IDH2-mutated AML, please see the [[Acute myeloid leukemia|main AML page]] for other regimens.'''</big> | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Revision as of 13:52, 10 May 2018
| Page editor | |
|---|---|
 |
Martin Schoen, MD, MPH Chicago, IL |
Note: these are biomarker-specific regimens for patients with IDH1 or IDH2-mutated AML, please see the main AML page for other regimens.
8 regimens on this page
8 variants on this page
|
Relapsed or refractory, salvage therapy
Enasidenib monotherapy
| back to top |
Regimen
| FDA-recommended dose |
| Study | Evidence | Efficacy |
|---|---|---|
| Stein et al. 2017 | Phase I/II | ORR: 40% |
This is the dose used in the phase II expansion cohort; enrolled patients were required to have IDH2-mutated advanced myeloid malignancies.
Chemotherapy
- Enasidenib (Idhifa) 100 mg PO once per day
28-day cycles
References
- Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722-731. Epub 2017 Jun 6. link to original article contains verified protocol link to PMC article PubMed